Meeting
2013 ASCO Annual Meeting
Effect of dose-optimized imatinib (IM) 800 mg on deep molecular responses (CMR 4.5) and prediction of survival: Results from the randomized CML-study IV.
Authors
Rüdiger Hehlmann
III. Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany
Rüdiger Hehlmann , Michael Lauseker , Benjamin Hanfstein , Martin C. Müller , Annette Schreiber , Ulrike Proetel , Markus Pfirrmann , Susanne Schnittger , Jolanta Dengler , Christiane Falge , Andreas Neubauer , Frank Stegelmann , Michael Pfreundschuh , Cornelius F. Waller , Karsten Spiekermann , Gabriela M. Baerlocher , Stefan W. Krause , Andreas Hochhaus , Joerg Hasford , Susanne Saussele
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT00055874
Citation
J Clin Oncol 31, 2013 (suppl; abstr 7051)
DOI
10.1200/jco.2013.31.15_suppl.7051
Abstract #
7051
Poster Bd #
36C
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.
First Author: Francois-Xaxier Mahon
Poster
2017 ASCO Annual Meeting
Ten-year survival after randomized comparison of imatinib (IM) 400 mg vs. IM 800 mg vs. IM + IFN vs. IM + Ara C vs. IM after IFN in chronic myeloid leukemia (CML).
First Author: Ruediger Hehlmann
First Author: Rüdiger Hehlmann
Poster
2014 ASCO Annual Meeting
EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients (pts) with newly diagnosed CP-CML.
First Author: Jeffrey Howard Lipton